Ocugen will report Q3 2026 results on 4 November 2026, a checkpoint on its OCU400 timeline and Roots licensing deal.

BioNTech plans to amend Phase 3 ROSETTA Breast-01 to test pumitamig with Gilead's Trodelvy instead of chemotherapy; the change needs regulatory approval.

MoffettNathanson trimmed its target but kept buy; Needham downgraded to hold. Netflix cut its 2026 ad revenue forecast to ...

UBTech signed a Japan distribution deal, began small U1 deliveries, and inked UAE and Xiamen C&D pacts — but only some are binding sales.

BYD fell 5.2% premarket as October retail sales dropped, following a 2.9% decline on CATL's miss. Analysts weigh sector weakness against company-specific updates.

Diginex shareholders approved the Resulticks deal with 98.8% support, but closing by Oct 30 hinges on Nasdaq listing approval and lender consents.

Nvidia plans telecom deployments, Google Cloud Rubin scale-up to 960,000 GPUs, and containerized AI factories via partners ...

Micron shares gain 2.1% on sector recovery as a 24-hour Taoyuan strike starts and a Taichung labor agreement eases some ...

Western Digital rose 3.9% Wednesday as BofA raised its target to $800 and Morgan Stanley cut to $643, both keeping bullish ...

Bernstein analyst James Hooper reaffirmed a Buy rating on BASF on Tuesday, holding his price target at 61 euros. The ...

About 2,000 trade unionists rallied in Strasbourg against the EU Inc draft, demanding binding guarantees for workers' rights as a committee vote slipped to 5 November.

BYD fell premarket as CATL's weak quarter hit the sector. September sales rose 16.98%, but nine-month sales fell 3.9%; Q3 results are due Oct 29.